Latest Breaking News On - Ophthalmic keratolytics - Page 1 : comparemela.com

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Study met its primary endpoint and showed significant and clinically meaningful improvements in multiple symptoms of Contact Lens Discomfort and signs of concomitant Meibomian Gland Dysfunction

United statesLyndon jonesAshwin agarwalJenna kaneMarc gleesonInternational workshop on contact lens discomfortResearch future fundAmerican optometric associationAzura primary researchCentre for ocular research education in ontarioAzura ophthalmics ltdContact lens discomfortMeibomian glandOphthalmic keratolyticsMeibomian gland dysfunctionMeibomian glands yielding liquid secretion

Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Socie

Robust safety and efficacy data supports advancing AZR-MD-001 into Phase 3 clinical trials TEL AVIV, Israel (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple pre.

San diegoUnited statesLisam nijmJenna kaneLimor miaraMarc gleesonFiona stapletonJenniferp craigPreeyak guptaUniversity of illinois eye ear infirmaryUniversity of south wales medicine healthMeetings for the association researchTulane universityAzura ophthalmics ltdAmerican society of cataractOphthalmic keratolytics

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian

TEL AVIV, Israel & MELBOURNE, Australia (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-0.

United statesSan diegoMarc gleesonAshwin agarwalTara mulloyJenna kaneAzura ophthalmics ltdAmerican optometric associationHealth commerceAzura primary researchInternational workshop on contact lens discomfortOphthalmic keratolyticsMeibomian gland dysfunctionOphthalmology innovation summitChief executive officerMeibomian glands yielding liquid secretion

Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U S and European Patents

Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U S and European Patents
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Marc gleesonAshwin agarwalTara mulloyAzura ophthalmics ltdTrademark officeInternational workshop on contact lens discomfortOphthalmic keratolyticsOphthalmics ltdMeibomian gland dysfunctionChief executive officerDry eye diseaseContact lens discomfortGland dysfunctionEvaporative dry eye diseaseAzura ophthalmicsContact lens interactions with

Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort

Press release content from Business Wire. The AP news staff was not involved in its creation.

New south walesMarc gleesonAshwin agarwalTara mulloyFiona stapletonAzura ophthalmics ltdSchool of optometryAustralian federal government medical research future fundInternational workshop on contact lens discomfortOphthalmic keratolyticsScientia professorVision scienceNew south wales sydneyAbout meibomian glandDry eye diseaseSelenium sulfide